Showing results (1-10 of 9) with videos related to
Sort By:
Pageof 1
Expert Opinion on Investigational Drugs|October 7, 2023
Bomedemstat as an investigative treatment for myeloproliferative neoplasmsHugh Young Rienhoff, Harinder GillMagnetic Resonance in Medicine|October 15, 2013
Cardiac R2* values are independent of the image analysis approach employedAntonella Meloni, Hugh Young Rienhoff, Amber Jones, et al.Magnetic Resonance Imaging|June 19, 2013
Fast approximation to pixelwise relaxivity maps: validation in iron overloaded subjectsAntonella Meloni, Heather Zmyewski, Hugh Young Rienhoff, et al.Plos One|May 26, 2012
Antimalarial iron chelator, FBS0701, shows asexual and gametocyte Plasmodium falciparum activity and single oral dose cure in a murine malaria modelPatricia Ferrer, Abhai K Tripathi, Martha A Clark, et al.Haematologica|December 22, 2010
A phase 1 dose-escalation study: safety, tolerability, and pharmacokinetics of FBS0701, a novel oral iron chelator for the treatment of transfusional iron overloadHugh Young Rienhoff, Vip Viprakasit, Lay Tay, et al.BMC Medical Genetics|February 19, 2020
Two monogenic disorders masquerading as one: severe congenital neutropenia with monocytosis and non-syndromic sensorineural hearing lossParvathy Venugopal, Lucia Gagliardi, Cecily Forsyth, et al.Blood|January 19, 2012
A phase 2 study of the safety, tolerability, and pharmacodynamics of FBS0701, a novel oral iron chelator, in transfusional iron overloadEllis J Neufeld, Renzo Galanello, Vip Viprakasit, et al.Blood Advances|February 27, 2026
Phase 2 study of the lysine-specific demethylase 1 (LSD1) inhibitor bomedemstat for essential thrombocythemiaHarinder Gill, Francesca Palandri, David M Ross, et al.Blood Advances|April 29, 2026
The lysine-specific demethylase 1 (LSD1) inhibitor bomedemstat in myelofibrosis: results from a phase 1/2 studyHarinder Gill, Abdulraheem Yacoub, Aaron T Gerds, et al.Pageof 1